表紙
市場調查報告書

老花眼:開發中產品分析

Presbyopia - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 410994
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
老花眼:開發中產品分析 Presbyopia - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 49 Pages
簡介

老花眼是一種眼睛慢慢失去快速聚焦在近物上的能力之眼睛狀況。老花眼會隨著年齡增長而發生。體徵和症狀包括頭痛,眼睛疲勞,閱讀小字困難和疲勞。危險因素包括貧血,糖尿病,心血管疾病,遠視,多發性硬化,重症肌無力和眼部創傷。

本報告提供老花眼的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

老花眼 概要

治療藥的開發

  • 開發中產品;概要

企業開發中的治療藥

開發中產品概況

  • 臨床實驗階段的產品
  • 初期階段的產品

企業開發中的產品

開發治療藥的企業

  • Allergan Plc
  • Encore Vision Inc
  • Orasis Pharmaceuticals Ltd
  • Presbyopia Therapies LLC
  • ViewPoint Therapeutics Inc

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (aceclidine + tropicamide)
  • (oxymetazoline hydrochloride + pilocarpine hydrochloride)
  • EV-06
  • lanosterol
  • oxymetazoline hydrochloride
  • PresbiDrops
  • VP-1001

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11793IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia - Pipeline Review, H2 2019, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape.

Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly on objects that are close. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis and eye trauma.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Presbyopia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Presbyopia (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Presbyopia (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Presbyopia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 2, 3 and 2 respectively.

Presbyopia (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Presbyopia (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Presbyopia (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Presbyopia (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Presbyopia (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Presbyopia (Ophthalmology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Presbyopia (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Presbyopia (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Presbyopia - Overview
    • Presbyopia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Presbyopia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Presbyopia - Companies Involved in Therapeutics Development
    • Acucela Inc
    • Allergan Plc
    • Cellix Bio Pvt Ltd
    • Eyenovia Inc
    • Kedalion Therapeutics Inc
    • Novartis AG
    • Ocuphire Pharma Inc
    • Orasis Pharmaceuticals Ltd
    • Plex Pharmaceuticals Inc
    • Presbyopia Therapies LLC
    • ViewPoint Therapeutics Inc
  • Presbyopia - Drug Profiles
  • Presbyopia - Dormant Projects
  • Presbyopia - Discontinued Products
  • Presbyopia - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Presbyopia, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Presbyopia - Pipeline by Acucela Inc, H2 2019
  • Presbyopia - Pipeline by Allergan Plc, H2 2019
  • Presbyopia - Pipeline by Cellix Bio Pvt Ltd, H2 2019
  • Presbyopia - Pipeline by Eyenovia Inc, H2 2019
  • Presbyopia - Pipeline by Kedalion Therapeutics Inc, H2 2019
  • Presbyopia - Pipeline by Novartis AG, H2 2019
  • Presbyopia - Pipeline by Ocuphire Pharma Inc, H2 2019
  • Presbyopia - Pipeline by Orasis Pharmaceuticals Ltd, H2 2019
  • Presbyopia - Pipeline by Plex Pharmaceuticals Inc, H2 2019
  • Presbyopia - Pipeline by Presbyopia Therapies LLC, H2 2019
  • Presbyopia - Pipeline by ViewPoint Therapeutics Inc, H2 2019
  • Presbyopia - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Presbyopia, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019